Globe Newswire (Wed, 18-Feb 9:00 AM ET)
Mesa Labs Announces Third Quarter Results
Globe Newswire (Tue, 3-Feb 8:00 AM ET)
MESA LABS DECLARES QUARTERLY DIVIDEND
Globe Newswire (Wed, 7-Jan 5:00 PM ET)
Mesa Labs to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026
Globe Newswire (Thu, 18-Dec 7:00 PM ET)
Upcoming Q3 Results Could Shift Outlook for MLAB—What to Watch Ahead of February 3 Announcement
Market Chameleon (Thu, 4-Dec 5:45 AM ET)
Mesa Laboratories Inc manufactures life sciences tools and critical quality control products. It operates in four divisions: Sterilization and Disinfection Control, which manufactures and sells biological, chemical, and cleaning indicators used to assess the effectiveness of sterilization, decontamination, disinfection, and cleaning processes. Clinical Genomics division develops, manufactures, and sells highly sensitive, low-cost, high-throughput genetic analysis tools and related consumables. The Biopharmaceutical Development division develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. The Calibration Solutions division develops, manufactures, sells, and services quality control products.
Mesa Laboratories trades on the NASDAQ stock market under the symbol MLAB.
As of March 6, 2026, MLAB stock price declined to $87.07 with 109,145 million shares trading.
MLAB has a beta of 1.20, meaning it tends to be more sensitive to market movements. MLAB has a correlation of 0.12 to the broad based SPY ETF.
MLAB has a market cap of $481.05 million. This is considered a Small Cap stock.
Last quarter Mesa Laboratories reported $65 million in Revenue and $3.07 earnings per share. This beat revenue expectation by $2 million and exceeded earnings estimates by $1.47.
In the last 3 years, MLAB traded as high as $187.75 and as low as $55.45.
The top ETF exchange traded funds that MLAB belongs to (by Net Assets): VTI, IWM, VXF, IWO, SCHA.
MLAB has underperformed the market in the last year with a price return of -36.5% while the SPY ETF gained +18.7%. However, in the short term, MLAB had mixed performance relative to the market. It has outperformed in the last 3 months, returning +12.4% vs -1.7% return in SPY. But in the last 2 weeks, MLAB shares have been beat by the market, returning -6.6% compared to an SPY return of -2.5%.
MLAB support price is $84.22 and resistance is $90.96 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MLAB shares will trade within this expected range on the day.